News

The Future Of Blockchain In Healthcare

The Future Of Blockchain In Healthcare 150 150 Doug DeMarra

Forbes

HealthVerity broadens appeal for its IPGE Platform with key executive hires

HealthVerity broadens appeal for its IPGE Platform with key executive hires 150 150 Doug DeMarra

PR Newswire

HealthVerity awarded CDC contract for real-world data to advance COVID-19 response

HealthVerity awarded CDC contract for real-world data to advance COVID-19 response 150 150 Doug DeMarra

HealthVerity awarded CDC contract for real-world data to advance COVID-19 response

OCTOBER 07, 2021

Award covers fully interoperable, patient-centric real-world data for over 100 million US patients using privacy-preserving record linkage.

PHILADELPHIA, PA — (PRNewswire) — HealthVerity, Inc., the leader in Identity, Privacy, Governance, and Exchange (IPGE) for real-world data, today announced that it has been awarded a contract with the Centers for Disease Control and Prevention (CDC) to provide a large-scale, fully interoperable, real-world dataset to advance a wide range of COVID-19 research, decision making, and public health impact objectives. Using Privacy-Preserving Record Linkage (PPRL), the HealthVerity data asset securely links de-identified patient-level data across medical and pharmacy claims, chargemaster, electronic medical records, and lab data, including genomic sequencing of COVID-19 variants, to generate comprehensive and longitudinal patient histories without sharing personally identifiable information.

The goal of this contract is to provide the CDC with a real-world dataset that is uniquely suited to provide novel insights into new and emerging priority questions related to SARS-CoV-2 variants, vaccinations, testing, re-infection, health impact, natural history, and the long-term effects of COVID-19. The data has high impact potential for CDC’s COVID-19 response and surveillance efforts because it offers CDC scientists the opportunity to conduct complex analyses and develop use cases on disease patterns, progression, and health outcomes. Leveraging its HealthVerity IPGE platform, including the nation’s largest privacy-protected healthcare and consumer data ecosystem, HealthVerity is assembling the largest, fully interoperable, real-world COVID-19 data asset ever acquired by the CDC.

“HealthVerity is proud to support the CDC in leveraging strategic data assets on its quest to understand the broad impact of COVID-19 on patients, healthcare systems, and communities,” said Andrew Kress, CEO at HealthVerity. “We are pleased that our expertise in patient identity resolution and privacy management combined with the broad cross-sectional healthcare and consumer data we manage on behalf of our data partners uniquely enables us to deliver a level of dimensionality for evidence generation that is critical to this major public health endeavor.”

In addition to COVID-19, the agreement provides the CDC with access to timely and comprehensive data on other key therapeutic areas such as viral hepatitis and HIV and the impact on key demographic groups, all in a privacy-protected, HIPAA-compliant manner.

HealthVerity has a history of serving key governmental health agencies to support public health initiatives. Most recently, HealthVerity supported the National Cancer Institute (NCI) for a groundbreaking study of SARS-CoV-2 antibodies in February 2021, announced a research contract with the U.S. Food and Drug Administration (FDA) to support COVID-19 clinical study and treatment opportunities in June 2020 and was awarded a PPRL contract for COVID-19 vaccine data with the Department of Health and Human Services (HHS) in November 2020.

About HealthVerity

Pharmaceutical manufacturers, payers, and government organizations have partnered with HealthVerity to solve some of their most complicated use cases through transformative technologies and real-world data infrastructure. The HealthVerity IPGE platform, based on the foundational elements of Identity, Privacy, Governance, and Exchange, enables the discovery of real-world data across the broadest healthcare data ecosystem, the building of more complete and accurate patient journeys and the ability to power best-in-class analytics and applications with flexibility and ease. Together with our partners, HealthVerity has built the modern way to data for the health insights economy. To learn more about the HealthVerity IPGE platform, visit www.healthverity.com.

Contact

Jen Kaczmarczyk
Vice President of Marketing
jkaczmarczyk@healthverity.com

REQUEST DEMO

HealthVerity IPGE is your answer for Identity, Privacy, Governance and Exchange.

To explore the power of the HealthVerity IPGE platform, fill out the form with your contact information.

HealthVerity announces agreement with Janssen to extend real-world data across their clinical trial portfolio

HealthVerity announces agreement with Janssen to extend real-world data across their clinical trial portfolio 150 150 Doug DeMarra

HealthVerity announces agreement with Janssen to extend real-world data across their clinical trial portfolio

SEPTEMBER 22, 2021

This collaboration enables direct access to privacy-compliant data at the patient level, across the broadest network of healthcare and consumer data sources.

PHILADELPHIA, PA — (PRNewswire) — Today HealthVerity announced an agreement with Janssen Research & Development, LLC (Janssen) to provide access to the HealthVerity IPGE platform, the largest linked real-world data ecosystem in the US, to further facilitate critical research and development activities. Prior work between HealthVerity and Janssen in data science highlights a broad set of R&D use cases, including:

  1. First-in-industry randomized control trial (RCT) to real-world data registry using data tokenization
  2. Developing real-world evidence (RWE) using external control arms (ECAs)
  3. Further optimize feasibility, site selection, patient recruitment, and increasing diversity and inclusion (D&I) in clinical trials with a singular goal of bringing life-saving and enhancing therapies to patients faster

“We’ve seen the need for real-time RWD to increase dramatically in the wake of COVID-19. The use of this data will continue to accelerate with the expanded focus on RWD to support research and development and regulatory decision making,” said Andrew Kress, CEO at HealthVerity. “In order to support this shift, our clients and data partners need us to help solve the challenge of how to apply this data at scale in a transformative way. The HealthVerity Identity, Privacy, Governance and Exchange (IPGE) platform provides access to record-level data, giving our clients the flexibility to run their own cutting-edge RWE and Data Science analytics and applications on numerous projects at once. We are pleased to collaborate with Janssen’s leading-edge R&D Data Science organization to put this capability into practice.”

The HealthVerity IPGE platform, integrated technology and RWD infrastructure – driven by identity, privacy, governance and exchange – enables organizations to connect and directly access the largest de-identified and privacy-compliant linked real-world dataset of 330 million US patients across the broadest network of data sources, including Medical and Pharmacy Claims, Electronic Health Records (EHR), Labs and Consumer data. The integrated multi-modal linkage capabilities of RWD to clinical trial patients allows the creation of longitudinal patient journeys supporting numerous use cases including Long Term Follow Up (LTFU) and Phase 4 studies.

About HealthVerity

Pharmaceutical manufacturers, payers, and government organizations have partnered with HealthVerity to solve some of their most complicated use cases through transformative technologies and real-world data infrastructure. The HealthVerity IPGE platform, based on the foundational elements of Identity, Privacy, Governance, and Exchange, enables the discovery of real-world data across the broadest healthcare data ecosystem, the building of more complete and accurate patient journeys and the ability to power best-in-class analytics and applications with flexibility and ease. Together with our partners, HealthVerity has built the modern way to data for the health insights economy. To learn more about the HealthVerity IPGE platform, visit www.healthverity.com.

Contact

Jen Kaczmarczyk
Vice President of Marketing
jkaczmarczyk@healthverity.com

REQUEST DEMO

HealthVerity IPGE is your answer for Identity, Privacy, Governance and Exchange.

To explore the power of the HealthVerity IPGE platform, fill out the form with your contact information.

After HeathVerity’s $100M Series D, the healthcare IT company will continue hiring to keep up with pandemic-fueled growth

After HeathVerity’s $100M Series D, the healthcare IT company will continue hiring to keep up with pandemic-fueled growth 150 150 Doug DeMarra

Technical.ly

After $100M Series D, HealthVerity CEO says an IPO could be next for the Philadelphia data firm

After $100M Series D, HealthVerity CEO says an IPO could be next for the Philadelphia data firm 150 150 Doug DeMarra

Philadelphia Business Journal

HealthVerity Raises $100M to Scale IPGE Platform, Market-Leading Technology and Real-World Data Infrastructure

HealthVerity Raises $100M to Scale IPGE Platform, Market-Leading Technology and Real-World Data Infrastructure 150 150 Doug DeMarra

HealthVerity Raises $100M to Scale IPGE Platform, Market-Leading Technology and Real-World Data Infrastructure

JUNE 28, 2021

The Series D round, led by Durable Capital Partners LP, will help scale platform capabilities, enabling secure data exchange across the broadest ecosystem.

PHILADELPHIA, PA — (BUSINESS NEWSWIRE) — HealthVerity announced today the close of $100 million in Series D funding to accelerate the growth of its IPGE (Identity, Privacy, Governance and Exchange) platform. This latest round of funding, led by Durable Capital Partners LP, with participation from all existing investors including Flare Capital Partners, Foresite Capital and Greycroft will help HealthVerity meet the increasing demand for its critical technologies empowering the health insights economy. Beyond accelerating go-to-market initiatives, the financing will fund expansion of the already existing largest real-world data ecosystem and industry-leading patient identity resolution technology.

“We are excited to partner with HealthVerity as it continues to build the next generation of modern technologies that will support the shift towards increased real-world data governance and privacy needs within healthcare,” said Henry Ellenbogen, Managing Partner & Chief Investment Officer at Durable Capital Partners LP. “After witnessing its growth over the past few years, I believe HealthVerity is uniquely positioned to provide solutions for many of the challenges around identity, privacy and governance that will help life sciences, payers and government agencies power secure and private data exchange across an array of patient-centric use cases. It has the potential to be a significant company.”

“Durable’s goal of partnering with high-growth, long-term transformative companies directly aligns with our mission at HealthVerity, where we have been consistent since our inception in our strategy and approach to evolving the healthcare data ecosystem and supporting our clients as they shift towards patient-centricity,” said Andrew Kress, CEO at HealthVerity. “We are so pleased to have them join the HealthVerity team.“

HealthVerity’s IPGE platform provides a unified infrastructure granting more than 250 leading healthcare enterprises and more than 80% of top pharmaceutical companies the ability to confidently leverage the technical capabilities of Identity, Privacy, Governance and Exchange to discover, access and apply real-world healthcare data to a multitude of use cases. Over the past year, HealthVerity’s growth has been accompanied by the selection from the Department of Health and Human Services (HHS) to deliver Privacy Preserving Record Linkage (PPRL) integrated in the COVID-19 vaccine rollout and partnerships with the FDA and NIH on multiple COVID-19 studies.

About Durable Capital Partners LP

Durable Capital Partners LP (“Durable”) is an investment manager focused on companies that have the potential to compound over time. Durable invests across private and public markets with a long-term horizon, applying deep knowledge of compounder patterns to support leaders building durable and sustainable businesses. Henry Ellenbogen, who previously was Portfolio Manager of T. Rowe Price’s New Horizon Fund, founded Durable in 2019.

About HealthVerity

Pharmaceutical manufacturers, payers, and government organizations have partnered with HealthVerity to solve some of their most complicated use cases through transformative technologies and real-world data infrastructure. The HealthVerity IPGE platform, based on the foundational elements of Identity, Privacy, Governance, and Exchange, enables the discovery of real-world data across the broadest healthcare data ecosystem, the building of more complete and accurate patient journeys and the ability to power best-in-class analytics and applications with flexibility and ease. Together with our partners, HealthVerity has built the modern way to data for the health insights economy. To learn more about the HealthVerity IPGE platform, visit www.healthverity.com.

Contact

HealthVerity
Colleen Stoker
cstoker@healthverity.com

REQUEST DEMO

HealthVerity IPGE is your answer for Identity, Privacy, Governance and Exchange.

To explore the power of the HealthVerity IPGE platform, fill out the form with your contact information.

Gilead’s Veklury® (Remdesivir) Associated With a Reduction in Mortality Rate in Hospitalized Patients With COVID-19 Across Three Analyses of Large Retrospective Real-World Data Sets

Gilead’s Veklury® (Remdesivir) Associated With a Reduction in Mortality Rate in Hospitalized Patients With COVID-19 Across Three Analyses of Large Retrospective Real-World Data Sets 150 150 Doug DeMarra

Gilead

HealthVerity Launches its IPGE Platform to Transform Real-World Data Discovery and Exchange for Pharma, Payers and Government

HealthVerity Launches its IPGE Platform to Transform Real-World Data Discovery and Exchange for Pharma, Payers and Government 150 150 Doug DeMarra

PR Newswire